| Filed On | Filing |
|---|---|
| 22 Oct 2026 |
Form 4: Brennan Daniel J., Director
Received 795 shares as a grant or award ($400K) |
| 22 Oct 2026 |
Form 3: Brennan Daniel J., Director
No securities owned |
| 20 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
(d) On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”). In connection with the appointment of Mr. Brennan, the size of the Boar... |
| 19 Oct 2026 |
Form 4: Sachs Bruce I, Director
Granted 92.694 Deferred Stock Units ($47.5K) |
| 19 Oct 2026 |
Form 4: Garber Alan M, Director
Granted 29.272 Deferred Stock Units ($15K) |
| 10 Sep 2026 |
Form 4: van Grunsven Jasper, EVP, CP and NPPO
Received 8,682 shares as a grant or award |
| 10 Sep 2026 |
Form 3: van Grunsven Jasper, EVP, CP and NPPO
No securities owned |
| 01 Sep 2026 |
Form 4: Ambrose Kristen, SVP & Chief Accounting Officer
Received 5,000 shares as a grant or award |
| 01 Sep 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 31 Aug 2026 |
Form 4: Sachs Bruce I, Director
Gave 6,000 shares as a gift |
| 27 Aug 2026 | 144 |
| 04 Aug 2026 | 10-Q |
| 03 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 23 Jul 2026 |
Form 4: Tatsis Ourania, EVP, Chief Reg. & Quality Off.
Received 8,251 shares as a grant or award |
| 23 Jul 2026 |
Form 4: Sachdev Amit, EVP Chief Patient & Ext Af Off
Received 8,251 shares as a grant or award |
| 17 Jul 2026 |
Form 4: Sachs Bruce I, Director
Granted 99.941 Deferred Stock Units ($47.5K) |
| 17 Jul 2026 |
Form 4: Garber Alan M, Director
Granted 31.56 Deferred Stock Units ($15K) |
| 07 Jul 2026 |
Form 4: Tatsis Ourania, EVP, Chief Reg. & Quality Off.
Sold 1,500 shares ($787K) |
| 07 Jul 2026 |
Form 4: McKechnie Duncan, EVP, Chief Commercial Officer
Sold 1,541 shares ($800K) |
| 07 Jul 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more |
Loading...
